1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)(phenyl)methyl]piperazine

• ChemBase ID: 238
• Molecular Formular: C28H33ClN2
• Molecular Mass: 433.02802
• Monoisotopic Mass: 432.23322675
• SMILES: Clc1ccc(C(N2CCN(CC2)Cc2ccc(C(C)(C)C)cc2)c2ccccc2)cc1
• Canonical SMILES: Clc1ccc(cc1)C(c1ccccc1)N1CCN(CC1)Cc1ccc(cc1)C(C)(C)C
• InChI: InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
• InChIKey: MOYGZHXDRJNJEP-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)(phenyl)methyl]piperazine
• IUPAC Traditional name: buclizine
• Brand Name: Aphilan R; Aphilan-R Base; Bucladin; Bucladin-S; Buclifen; Buclina; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Histabutyzine Dihydrochloride; Histabutyzine Hydrochloride; Hitabutyzyne; Longifene; Posdel; Postafen; Softran; Vibazine
• Synonyms: Buclizina [INN-Spanish]; Buclizine Dihydrochloride; Buclizine Hydrochloride; Buclizinum [INN-Latin]; Histabutyzine Dihydrochloride; Vibazine Hydrochloride; Buclizine

Database IDs

• CAS Number: 82-95-1
• PubChem SID: 160963701; 46507608
• PubChem CID: 6729
• CHEBI ID: 3205
• ATC CODE: R06AE01
• CHEMBL: 1201271
• Chemspider ID: 6473
• DrugBank ID: DB00354
• Unique Ingredient Identifier: 0C94V6X681
• Wikipedia Title: Buclizine

CALCULATED PROPERTIES

JChem

• H Acceptors: 2
• H Donor: 0
• LogD (pH = 5.5): 4.9219527
• LogD (pH = 7.4): 6.6895
• Log P: 7.4195766
• Molar Refractivity: 133.0169 cm^3
• Polarizability: 52.113827 Å^3
• Polar Surface Area: 6.48 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 6.16
• LOG S: -6.25
• Solubility (Water): 2.46e-04 g/l

PROPERTIES

Physical Property

• Hydrophobicity(logP): 7.1

DETAILS

DrugBank - DB00354

• Drug Groups: approved
• Description: Buclizine is an antihistamine of the piperazine derivative family. [Wikipedia]
• Indication: For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
• Pharmacology: Buclizine is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Buclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which buclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.
• Absorption: Rapidly absorbed following oral administration.
• External Links: Wikipedia